Study guide

8.2 Investigator Responsibilities under GCP

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

8.2 Investigator Responsibilities under GCP

Key Takeaways Explain This Topic AI

The Principal Investigator (PI) has ultimate responsibility for the conduct of the trial at the site, even when delegating specific tasks to the site team.

The PI must ensure adequate resources, qualifications of staff, and proper medical care for trial subjects.

Source data must meet ALCOA-C standards: Attributable, Legible, Contemporaneous, Original, Accurate, and Complete.

Last updated: October 2026

Investigator Responsibilities under GCP

The Principal Investigator (PI) is the leader of the clinical trial team at the research site. Under Good Clinical Practice (GCP), the PI holds the ultimate responsibility for the ethical and scientific conduct of the trial. While a Clinical Research Coordinator (CRC) performs many of the day-to-day operational tasks, they do so under the direct supervision and delegation of the PI. Understanding the PI's responsibilities is crucial for a CRC, as it dictates how tasks must be documented, overseen, and reported.

Ultimate Responsibility and Delegation

A fundamental tenet of GCP is that while the PI may delegate trial-related duties to appropriately qualified individuals, the PI cannot delegate responsibility.

The Delegation of Authority (DOA) Log

The DOA log is a critical regulatory document that formally assigns specific trial tasks to site personnel.

Proportionate Record : ICH E6(R3) 2.3.3 asks for a record of the persons and parties to whom trial-related activities are delegated, proportionate to the significance of the activities; activities performed as part of clinical practice may not need delegation documentation.

Qualifications : The PI must ensure that any individual delegated a task is qualified by education, training, and experience. For example, delegating the administration of an intravenous investigational drug must go to a registered nurse or physician, not an unlicensed data entry clerk.

Ongoing Oversight : The PI must maintain continuous oversight of all delegated tasks. This is typically demonstrated through regular team meetings, documented review of clinical data, and the PI's signature on key documents like lab reports and electronic Case Report Forms (eCRFs).

Third-Party Vendors : If the PI uses a service provider for trial-related activities (e.g., an external radiology facility or a home-nursing service), the PI decides whether it is suitable, even when the sponsor suggested it, documents the agreement, and keeps oversight proportionate to the risks (ICH E6(R3) 2.3.1 and 2.3.4).

Adequate Resources and Medical Care

Before accepting a trial, the PI must ensure the site has the capacity to conduct it properly.

Demonstrating Adequate Resources

Time and Staff : The PI must have sufficient time to properly conduct and complete the trial within the agreed period. The site must have an adequate number of qualified staff and adequate facilities.

Patient Population : The PI must be able to demonstrate a potential for recruiting the required number of suitable subjects within the agreed recruitment period, often supported by a retrospective review of electronic health records.

Medical Care of Trial Subjects

Qualified Investigator : A qualified physician or, where appropriate, a qualified dentist (or other qualified healthcare professional where local rules allow) who is the PI or a sub-investigator must be responsible for trial-related medical care and decisions (ICH E6(R3) 2.7.1(a)).

Primary Care Communication : With the subject's consent, the PI should inform the subject's primary physician about their participation in the trial.

Adverse Events (AEs) : The PI must ensure adequate medical care is provided for any AEs, including clinically significant laboratory abnormalities, related to the trial. The PI must include a causality assessment (relationship to the investigational product) with every SAE report, and assess other AEs for causality when the protocol requires it.

Communication with the IRB/IEC

The PI serves as the primary liaison between the site and the Institutional Review Board (IRB) or Independent Ethics Committee (IEC).

Initial Approval : The PI must obtain written and dated approval from the IRB for the protocol, informed consent form, subject recruitment procedures, and any other written information provided to subjects.

Ongoing Reporting : ICH E6(R3) 1.4.8 lists what the investigator reports promptly to the IRB/IEC: deviations made to eliminate immediate hazards, changes that increase risk to participants or significantly affect the trial, SUSARs (in accordance with applicable regulatory requirements), and new information that may adversely affect participant safety or trial conduct. In the US, all unanticipated problems involving risks to participants are reported promptly (21 CFR 312.66); other deviations are reported as the IRB's procedures require.

Status Summaries : The investigator or sponsor submits documented summaries of the trial status to the IRB/IEC as local regulatory requirements specify or on request (ICH E6(R3) 2.4.5); in the US, IRB continuing review takes place at least once a year (21 CFR 56.109(f)).

Source Documentation and ALCOA-C

A significant portion of PI responsibility revolves around data integrity. The PI must ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor. ICH E6(R3) 2.12.2 states that source records should be attributable, legible, contemporaneous, original, accurate and complete, often summarized as ALCOA-C:

Principle Definition Practical Application for the Site Team

Attributable It must be clear who created or modified the record. Staff must sign and date entries, or use secure electronic signatures. Never share passwords for EDC systems.

Legible The record must be readable and decipherable. Use clear handwriting. If an error is made, use a single line-through, initial, and date; never use correction fluid (white-out).

Contemporaneous Data must be recorded at the time the observation or activity occurred. Write down vital signs immediately when taken, not hours later at the end of the shift.

Original The first capture of the data, whether on paper or electronic. If a weight is jotted on a sticky note and then typed into an EMR, the sticky note is technically the original source. Sites should capture data directly into permanent records.

Accurate The data must truthfully reflect the observation. Calibrate equipment regularly (e.g., blood pressure cuffs, scales) to ensure measurements are correct.

Complete All required data elements are present. Ensure all blanks on a form are filled. Use "ND" (Not Done) or "NA" (Not Applicable) to explain empty fields.

Investigational Product (IP) Management

The PI is responsible for IP accountability at the site. While often delegated to an investigational pharmacist or CRC, the PI must ensure:

IP is stored as specified by the sponsor and regulatory requirements.

IP is supplied only to subjects enrolled in the trial and strictly according to the protocol.

Detailed records of IP delivery, inventory, use by subjects, and return or destruction are maintained.